Please login to the form below

Not currently logged in
Email:
Password:

I-Mab

This page shows the latest I-Mab news and features for those working in and with pharma, biotech and healthcare.

Morphosys’ Darzalex patent challenge hits a hurdle

Morphosys’ Darzalex patent challenge hits a hurdle

China in the first quarter of this year with the help of partner I-Mab, which licensed rights to the drug in mainland China, Hong Kong, Macau and Taiwan in November

Latest news

  • Biologics at forefront

    anti-IL 21 MAb (autoimmune/inflammatory disease)   . Preclinical . 181.5. Intercell/GSK Biologicals . patch-based vaccines  .  . ... 5m at the start of phase I studies on the IL-21 MAb, plus royalties on net sales.

More from news
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Acquisition - company. $600. Boehringer Ingelheim/ AbbVie. BI-655066: anti-IL-23 MAb in Phase III for psoriasis and other autoimmune disorders; and BI-655064: anti-CD-40 MAb in Phase I. ... Acquisition – company. $200. TaiMed/ Theratechnologies.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics